Coagulation Disorders in Chronic Liver Disease
Summary
Chronic liver disease disrupts the delicate balance of the coagulation system by impairing synthesis of both pro- and anti-coagulant factors. As liver fibrosis advances, production of clotting factors II, V, VII, IX and X diminishes, while levels of natural anticoagulants such as protein C, protein S and antithrombin also fall. Thrombocytopenia, arising from splenic sequestration, reduced thrombopoietin production and bone marrow suppression, further compromises primary haemostasis. Despite these changes, a concept of rebalanced haemostasis has emerged: concurrent reductions in pro- and anti-coagulant pathways may preserve overall clotting equilibrium, but render patients simultaneously vulnerable to bleeding and thrombosis. Clinically, this dual risk manifests as mucosal bleeding, coagulopathy during invasive procedures, and an elevated incidence of portal vein thrombosis. Management involves careful assessment of bleeding risk versus thrombotic potential: prophylactic transfusion or administration of thrombopoietin receptor agonists may be indicated before intervention, whereas anticoagulation can prevent or treat splanchnic vein thrombosis without substantially increasing haemorrhagic complications. Emerging precision-medicine tools and refined understanding of the rebalanced state promise to improve prediction, prevention and treatment of coagulation disorders in this population.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Coagulation Disorders in Chronic Liver Disease publication trend
The graph below shows the total number of articles in coagulation disorders in chronic liver disease across all publications each year (not limited to Nature Index journals).
Technical terms
Rebalanced haemostasis: a state in which parallel reductions in clot-promoting and clot-inhibiting factors maintain overall coagulation equilibrium.
Thrombocytopenia: a decrease in circulating platelet count that heightens bleeding risk and complicates invasive procedures.
Portal vein thrombosis: occlusion of the portal vein by a blood clot, common in advanced liver disease and associated with portal hypertension.
Thrombopoietin receptor agonists: agents that stimulate platelet production by mimicking the action of thrombopoietin on bone marrow megakaryocytes.
References
- Diagnostic Prediction of portal vein thrombosis in chronic cirrhosis patients using data-driven precision medicine model. Briefings in Bioinformatics (2023).
- Approach to different thrombolysis techniques and timing of thrombolysis in the management of portal vein thrombosis in cirrhotic patients. Journal of Translational Internal Medicine (2023).
- Thrombocytopenia in chronic liver disease. Liver International (2016).
- A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation. Journal of Gastroenterology (2018).
- Haemostatic alterations and management of haemostasis in patients with cirrhosis. Journal of Hepatology (2022).
- Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. Wiener klinische Wochenschrift (2018).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.